MedDataX Logo

Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

NCT ID: NCT01246375

Last Updated: 2010-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dual energy X-ray absorptiometry

Device which measures bone density

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Man at the minimum age of 60 years.
2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease.
3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years:

Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion Criteria

1. Usage of systemic steroids more than once during the 12 months prior to the study.
2. Usage of systemic steroids during the month prior to the study.
3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.
Minimum Eligible Age

60 Years

Maximum Eligible Age

90 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tel Aviv medical center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yehuda Schwartz, M.D

Role: PRINCIPAL_INVESTIGATOR

Tel Aviv Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tel Aviv medical center

Tel Aviv, Israel, Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eitan Segal, B.Sc

Role: CONTACT

Phone: 97236947507

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Eitan segal, B.Sc

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TASMC-10-SY-454-CTIL

Identifier Type: -

Identifier Source: org_study_id